AU2003283688A1 - Controlled-release of an active substance into a high fat environment - Google Patents

Controlled-release of an active substance into a high fat environment Download PDF

Info

Publication number
AU2003283688A1
AU2003283688A1 AU2003283688A AU2003283688A AU2003283688A1 AU 2003283688 A1 AU2003283688 A1 AU 2003283688A1 AU 2003283688 A AU2003283688 A AU 2003283688A AU 2003283688 A AU2003283688 A AU 2003283688A AU 2003283688 A1 AU2003283688 A1 AU 2003283688A1
Authority
AU
Australia
Prior art keywords
use environment
composition
release
fold
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003283688A
Other languages
English (en)
Inventor
Mark Brian Chidlaw
Dwayne Thomas Friesen
Scott Max Herbig
James Alan Schriver Nightingale
Cynthia Ann Oksanen
James Blair West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2003283688A1 publication Critical patent/AU2003283688A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003283688A 2002-12-11 2003-11-28 Controlled-release of an active substance into a high fat environment Abandoned AU2003283688A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43286002P 2002-12-11 2002-12-11
US60/432,860 2002-12-11
PCT/IB2003/005629 WO2004052343A1 (en) 2002-12-11 2003-11-28 Controlled-release of an active substance into a high fat environment

Publications (1)

Publication Number Publication Date
AU2003283688A1 true AU2003283688A1 (en) 2004-06-30

Family

ID=32508002

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003283688A Abandoned AU2003283688A1 (en) 2002-12-11 2003-11-28 Controlled-release of an active substance into a high fat environment

Country Status (18)

Country Link
US (1) US20040121015A1 (enExample)
EP (1) EP1572163A1 (enExample)
JP (1) JP2006510655A (enExample)
KR (1) KR20050088311A (enExample)
CN (1) CN1726012A (enExample)
AR (1) AR042340A1 (enExample)
AU (1) AU2003283688A1 (enExample)
BR (1) BR0317275A (enExample)
CA (1) CA2508722A1 (enExample)
CO (1) CO5570656A2 (enExample)
MX (1) MXPA05005812A (enExample)
NO (1) NO20053068L (enExample)
NZ (1) NZ539915A (enExample)
PL (1) PL377479A1 (enExample)
RU (1) RU2308263C2 (enExample)
TW (1) TWI257302B (enExample)
WO (1) WO2004052343A1 (enExample)
ZA (1) ZA200503812B (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003246791A1 (en) * 2002-04-09 2003-10-20 Flamel Technologies Oral suspension of amoxicillin capsules
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
ATE418968T1 (de) * 2005-01-28 2009-01-15 Pfizer Prod Inc Schnell zerfallendes mikroporöses bindemittel und herstellungsverfahren dafür
ES2403069T3 (es) * 2005-02-22 2013-05-13 Sun Pharma Advanced Research Company Ltd Composición oral de liberación controlada que contiene levetiracetam
EP1874282B1 (en) * 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US8730031B2 (en) 2005-04-28 2014-05-20 Proteus Digital Health, Inc. Communication system using an implantable device
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US8847766B2 (en) 2005-04-28 2014-09-30 Proteus Digital Health, Inc. Pharma-informatics system
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
US8547248B2 (en) 2005-09-01 2013-10-01 Proteus Digital Health, Inc. Implantable zero-wire communications system
EP3367386A1 (en) 2006-05-02 2018-08-29 Proteus Digital Health, Inc. Patient customized therapeutic regimens
ATE535057T1 (de) 2006-10-17 2011-12-15 Proteus Biomedical Inc Niederspannungsoszillator für medizinische einrichtungen
MY158019A (en) 2006-10-25 2016-08-30 Proteus Digital Health Inc Controlled activation ingestible identifier
WO2008063626A2 (en) 2006-11-20 2008-05-29 Proteus Biomedical, Inc. Active signal processing personal health signal receivers
EP2107883A4 (en) 2007-02-01 2013-07-03 Proteus Digital Health Inc SYSTEMS WITH EFFECTIVE EVENT MARKERS
JP5614991B2 (ja) * 2007-02-14 2014-10-29 プロテウス デジタル ヘルス， インコーポレイテッド 大表面積電極を有する体内型電源
EP2063771A1 (en) 2007-03-09 2009-06-03 Proteus Biomedical, Inc. In-body device having a deployable antenna
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
US8115618B2 (en) 2007-05-24 2012-02-14 Proteus Biomedical, Inc. RFID antenna for in-body device
PT2192946T (pt) 2007-09-25 2022-11-17 Otsuka Pharma Co Ltd Dispositivo no corpo com amplificação de sinal dipolo virtual
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
KR100920106B1 (ko) * 2007-11-14 2009-10-01 경북대학교 산학협력단 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치
CA2717809A1 (en) 2007-11-27 2009-06-04 Proteus Biomedical, Inc. Transbody communication systems employing communication channels
ES2636844T3 (es) 2008-03-05 2017-10-09 Proteus Biomedical, Inc. Sistemas y marcadores de eventos ingeribles de comunicación multimodo, y métodos para usarlos
DK2313002T3 (en) 2008-07-08 2018-12-03 Proteus Digital Health Inc Data basis for edible event fields
KR101214453B1 (ko) 2008-08-13 2012-12-24 프로테우스 디지털 헬스, 인코포레이티드 복용 가능한 회로
CN117530912A (zh) 2008-08-15 2024-02-09 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
US8036748B2 (en) * 2008-11-13 2011-10-11 Proteus Biomedical, Inc. Ingestible therapy activator system and method
WO2010068818A2 (en) * 2008-12-11 2010-06-17 Proteus Biomedical, Inc. Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
TWI424832B (zh) 2008-12-15 2014-02-01 Proteus Digital Health Inc 與身體有關的接收器及其方法
US9883819B2 (en) 2009-01-06 2018-02-06 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
TWI602561B (zh) 2009-01-06 2017-10-21 波提亞斯數位康健公司 醫藥劑量傳送系統
WO2010111403A2 (en) 2009-03-25 2010-09-30 Proteus Biomedical, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
EA201190281A1 (ru) 2009-04-28 2012-04-30 Протиус Байомедикал, Инк. Высоконадежные проглатываемые отметчики режима и способы их применения
US9149423B2 (en) 2009-05-12 2015-10-06 Proteus Digital Health, Inc. Ingestible event markers comprising an ingestible component
MX2012001660A (es) 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
WO2011022732A2 (en) 2009-08-21 2011-02-24 Proteus Biomedical, Inc. Apparatus and method for measuring biochemical parameters
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
UA109424C2 (uk) 2009-12-02 2015-08-25 Фармацевтичний продукт, фармацевтична таблетка з електронним маркером і спосіб виготовлення фармацевтичної таблетки
RU2587795C2 (ru) 2010-02-01 2016-06-20 Проутьюс Диджитал Хэлс, Инк. Система сбора данных
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
EA201290799A1 (ru) 2010-02-17 2013-03-29 Айронвуд Фармасьютикалз, Инк. Лечение желудочно-кишечных расстройств
US9597487B2 (en) 2010-04-07 2017-03-21 Proteus Digital Health, Inc. Miniature ingestible device
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
LT2603232T (lt) 2010-08-11 2020-01-27 Ironwood Pharmaceuticals, Inc. Stabilios linaklotido vaisto formos
WO2012071280A2 (en) 2010-11-22 2012-05-31 Proteus Biomedical, Inc. Ingestible device with pharmaceutical product
WO2012125425A2 (en) 2011-03-11 2012-09-20 Proteus Biomedical, Inc. Wearable personal body associated device with various physical configurations
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
AU2012284125A1 (en) 2011-07-21 2014-02-06 Proteus Digital Health, Inc. Mobile communication device, system, and method
MX347354B (es) 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
ES2967970T3 (es) 2012-07-23 2024-05-06 Otsuka Pharma Co Ltd Técnicas para fabricar marcadores de eventos ingeribles que comprenden un componente ingerible
EP2910013B1 (en) 2012-10-18 2018-05-16 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
TWI659994B (zh) 2013-01-29 2019-05-21 美商普羅托斯數位健康公司 高度可膨脹之聚合型薄膜及包含彼之組成物
WO2014151929A1 (en) 2013-03-15 2014-09-25 Proteus Digital Health, Inc. Personal authentication apparatus system and method
JP5941240B2 (ja) 2013-03-15 2016-06-29 プロテウス デジタル ヘルス， インコーポレイテッド 金属検出器装置、システム、および方法
JP6511439B2 (ja) 2013-06-04 2019-05-15 プロテウス デジタル ヘルス， インコーポレイテッド データ収集および転帰の査定のためのシステム、装置、および方法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
AU2014321320B2 (en) 2013-09-20 2019-03-14 Otsuka Pharmaceutical Co., Ltd. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9577864B2 (en) 2013-09-24 2017-02-21 Proteus Digital Health, Inc. Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
RU2711058C1 (ru) 2016-07-22 2020-01-14 Протеус Диджитал Хелс, Инк. Электромагнитное зондирование и обнаружение проглатываемых маркеров событий
EP3531901A4 (en) 2016-10-26 2021-01-27 Proteus Digital Health, Inc. METHOD OF MANUFACTURING CAPSULES WITH TAKE-UP EVENT MARKERS
CN111214456A (zh) * 2020-03-10 2020-06-02 浙江普利药业有限公司 伏立康唑干混悬剂及其制备方法
CR20230109A (es) * 2020-07-30 2023-05-11 Faes Farma Sa Sistema de liberación de fármacos descongestivos y bilastina
CN112198274B (zh) * 2020-11-02 2022-04-05 北京市理化分析测试中心 一种检测氨酚伪麻片中盐酸伪麻黄碱的方法
CN113514579A (zh) * 2021-06-23 2021-10-19 远大生命科学(武汉)有限公司 一种依托咪酯乳状注射液体外释放曲线的测定方法
CN115647000B (zh) * 2022-10-26 2025-06-27 华能阜新风力发电有限责任公司 一种基于低温热解的风电叶片回收方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4203439A (en) * 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
MX9301823A (es) * 1992-03-30 1994-01-31 Alza Corp Composicion para el suministro de liberacion controlado de un agente biologicamente activo.
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
EP0914098B1 (en) * 1997-05-30 2003-10-01 Osmotica Corp. Multi-layered osmotic device
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system

Also Published As

Publication number Publication date
CO5570656A2 (es) 2005-10-31
NO20053068D0 (no) 2005-06-22
EP1572163A1 (en) 2005-09-14
TW200425888A (en) 2004-12-01
CN1726012A (zh) 2006-01-25
CA2508722A1 (en) 2004-06-24
RU2308263C2 (ru) 2007-10-20
RU2005118101A (ru) 2006-01-20
US20040121015A1 (en) 2004-06-24
NZ539915A (en) 2007-09-28
ZA200503812B (en) 2006-07-26
WO2004052343A1 (en) 2004-06-24
NO20053068L (no) 2005-09-07
MXPA05005812A (es) 2005-08-16
AR042340A1 (es) 2005-06-15
KR20050088311A (ko) 2005-09-05
JP2006510655A (ja) 2006-03-30
BR0317275A (pt) 2005-11-08
TWI257302B (en) 2006-07-01
PL377479A1 (pl) 2006-02-06

Similar Documents

Publication Publication Date Title
US20040121015A1 (en) Controlled-Release of an active substance into a high fat environment
EP1242055B1 (en) Hydrogel-driven drug dosage form
Sungthongjeen et al. Development of pulsatile release tablets with swelling and rupturable layers
BG107538A (bg) Дозирана лекарствена форма с хидрогелен механизъм
RU2325163C2 (ru) Композиции с пролонгированным высвобождением, включающие ламотригин
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US20240000701A1 (en) Self-regulating osmotic gastroretentive drug delivery systems
KR20220151016A (ko) 토파시티닙 경구용 지속 방출 투여 형태
KR20080008352A (ko) 페노피브르산 및/또는 이의 염을 포함하는 경구 약제학적제형
JP5105684B2 (ja) 持続性医薬製剤
WO2021014360A1 (en) Oral modified release dosage forms
HK1083588A (en) Controlled-release of an active substance into a high fat environment

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application